Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
350 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Inflammatory Bowel Disease - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2014', provides an overview of the Inflammatory Bowel Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Inflammatory Bowel Disease Overview 8 Therapeutics Development 9 Inflammatory Bowel Disease - Therapeutics under Development by Companies 11 Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes 19 Inflammatory Bowel Disease - Pipeline Products Glance 21 Inflammatory Bowel Disease - Products under Development by Companies 24 Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes 32 Inflammatory Bowel Disease - Companies Involved in Therapeutics Development 33 Inflammatory Bowel Disease - Therapeutics Assessment 108 Drug Profiles 122 Inflammatory Bowel Disease - Recent Pipeline Updates 289 Inflammatory Bowel Disease - Dormant Projects 317 Inflammatory Bowel Disease - Discontinued Products 326 Inflammatory Bowel Disease - Product Development Milestones 327 Appendix 334
List of Tables Number of Products under Development for Inflammatory Bowel Disease, H2 2014 24 Number of Products under Development for Inflammatory Bowel Disease - Comparative Analysis, H2 2014 25 Number of Products under Development by Companies, H2 2014 27 Number of Products under Development by Companies, H2 2014 (Contd..1) 28 Number of Products under Development by Companies, H2 2014 (Contd..2) 29 Number of Products under Development by Companies, H2 2014 (Contd..3) 30 Number of Products under Development by Companies, H2 2014 (Contd..4) 31 Number of Products under Development by Companies, H2 2014 (Contd..5) 32 Number of Products under Development by Companies, H2 2014 (Contd..6) 33 Number of Products under Investigation by Universities/Institutes, H2 2014 35 Comparative Analysis by Clinical Stage Development, H2 2014 36 Comparative Analysis by Early Stage Development, H2 2014 37 Comparative Analysis by Unknown Stage Development, H2 2014 38 Products under Development by Companies, H2 2014 39 Products under Development by Companies, H2 2014 (Contd..1) 40 Products under Development by Companies, H2 2014 (Contd..2) 41 Products under Development by Companies, H2 2014 (Contd..3) 42 Products under Development by Companies, H2 2014 (Contd..4) 43 Products under Development by Companies, H2 2014 (Contd..5) 44 Products under Development by Companies, H2 2014 (Contd..6) 45 Products under Development by Companies, H2 2014 (Contd..7) 46 Products under Investigation by Universities/Institutes, H2 2014 47 Inflammatory Bowel Disease - Pipeline by 4SC AG, H2 2014 48 Inflammatory Bowel Disease - Pipeline by ActogeniX NV, H2 2014 49 Inflammatory Bowel Disease - Pipeline by Addex Therapeutics Ltd, H2 2014 50 Inflammatory Bowel Disease - Pipeline by Advinus Therapeutics Ltd., H2 2014 51 Inflammatory Bowel Disease - Pipeline by Aerpio Therapeutics, Inc., H2 2014 52 Inflammatory Bowel Disease - Pipeline by AlbireoPharma, H2 2014 53 Inflammatory Bowel Disease - Pipeline by Am-Pharma B.V., H2 2014 54 Inflammatory Bowel Disease - Pipeline by Amakem NV, H2 2014 55 Inflammatory Bowel Disease - Pipeline by Amgen Inc., H2 2014 56 Inflammatory Bowel Disease - Pipeline by Amorepacific Corporation, H2 2014 57 Inflammatory Bowel Disease - Pipeline by Aquinox Pharmaceuticals Inc., H2 2014 58 Inflammatory Bowel Disease - Pipeline by Ardelyx, Inc., H2 2014 59 Inflammatory Bowel Disease - Pipeline by Argos Therapeutics, Inc., H2 2014 60 Inflammatory Bowel Disease - Pipeline by ASKA Pharmaceutical Co., Ltd., H2 2014 61 Inflammatory Bowel Disease - Pipeline by Axxam SpA, H2 2014 62 Inflammatory Bowel Disease - Pipeline by Basilea Pharmaceutica AG, H2 2014 63 Inflammatory Bowel Disease - Pipeline by BioLineRx, Ltd., H2 2014 64 Inflammatory Bowel Disease - Pipeline by Biotec Pharmacon ASA, H2 2014 65 Inflammatory Bowel Disease - Pipeline by BioTherapeutics Inc., H2 2014 66 Inflammatory Bowel Disease - Pipeline by Blueberry Therapeutics Ltd, H2 2014 67 Inflammatory Bowel Disease - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2014 68 Inflammatory Bowel Disease - Pipeline by Celsus Therapeutics Plc, H2 2014 69 Inflammatory Bowel Disease - Pipeline by ChemoCentryx, Inc., H2 2014 70 Inflammatory Bowel Disease - Pipeline by ChironWells GmbH, H2 2014 71 Inflammatory Bowel Disease - Pipeline by Compugen Ltd., H2 2014 72 Inflammatory Bowel Disease - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 73 Inflammatory Bowel Disease - Pipeline by Creabilis SA, H2 2014 74 Inflammatory Bowel Disease - Pipeline by Delenex Therapeutics AG, H2 2014 75 Inflammatory Bowel Disease - Pipeline by Eisai Co., Ltd., H2 2014 76 Inflammatory Bowel Disease - Pipeline by Emergent BioSolutions Inc., H2 2014 77 Inflammatory Bowel Disease - Pipeline by Galapagos NV, H2 2014 78 Inflammatory Bowel Disease - Pipeline by Genentech, Inc., H2 2014 79 Inflammatory Bowel Disease - Pipeline by Genfit SA, H2 2014 80 Inflammatory Bowel Disease - Pipeline by GlaxoSmithKline plc, H2 2014 81 Inflammatory Bowel Disease - Pipeline by GlycoMar Limited, H2 2014 82 Inflammatory Bowel Disease - Pipeline by iCo Therapeutics Inc., H2 2014 83 Inflammatory Bowel Disease - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 84 Inflammatory Bowel Disease - Pipeline by Janssen Biotech, Inc., H2 2014 85 Inflammatory Bowel Disease - Pipeline by Kineta, Inc., H2 2014 86 Inflammatory Bowel Disease - Pipeline by Kymab Limited, H2 2014 87 Inflammatory Bowel Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 88 Inflammatory Bowel Disease - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2014 89 Inflammatory Bowel Disease - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2014 90 Inflammatory Bowel Disease - Pipeline by Lycera Corp., H2 2014 91 Inflammatory Bowel Disease - Pipeline by Medestea Research & Production S.p.A., H2 2014 92 Inflammatory Bowel Disease - Pipeline by Medgenics Inc., H2 2014 93 Inflammatory Bowel Disease - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 94 Inflammatory Bowel Disease - Pipeline by N30 Pharmaceuticals, H2 2014 95 Inflammatory Bowel Disease - Pipeline by Nogra Pharma Limited, H2 2014 96 Inflammatory Bowel Disease - Pipeline by Novozymes A/S, H2 2014 97 Inflammatory Bowel Disease - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 98 Inflammatory Bowel Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 99 Inflammatory Bowel Disease - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 100 Inflammatory Bowel Disease - Pipeline by Opsona Therapeutics Ltd., H2 2014 101 Inflammatory Bowel Disease - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 102 Inflammatory Bowel Disease - Pipeline by Pepscan Therapeutics, H2 2014 103 Inflammatory Bowel Disease - Pipeline by ProtAb Ltd, H2 2014 104 Inflammatory Bowel Disease - Pipeline by Protagonist Therapeutics Inc., H2 2014 105 Inflammatory Bowel Disease - Pipeline by RaQualia Pharma Inc., H2 2014 106 Inflammatory Bowel Disease - Pipeline by ReveraGen BioPharma, Inc., H2 2014 107 Inflammatory Bowel Disease - Pipeline by Rottapharm SpA, H2 2014 108 Inflammatory Bowel Disease - Pipeline by Salix Pharmaceuticals Ltd., H2 2014 109 Inflammatory Bowel Disease - Pipeline by Saniona AB, H2 2014 110 Inflammatory Bowel Disease - Pipeline by Sanofi, H2 2014 111 Inflammatory Bowel Disease - Pipeline by Sareum Holdings plc, H2 2014 112 Inflammatory Bowel Disease - Pipeline by Sigmoid Pharma Limited, H2 2014 113 Inflammatory Bowel Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 114 Inflammatory Bowel Disease - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2014 115 Inflammatory Bowel Disease - Pipeline by Synovo GmbH, H2 2014 116 Inflammatory Bowel Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 117 Inflammatory Bowel Disease - Pipeline by TiGenix NV, H2 2014 118 Inflammatory Bowel Disease - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 119 Inflammatory Bowel Disease - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 120 Inflammatory Bowel Disease - Pipeline by Ventria Bioscience, H2 2014 121 Inflammatory Bowel Disease - Pipeline by Zealand Pharma A/S, H2 2014 122 Assessment by Monotherapy Products, H2 2014 123 Assessment by Combination Products, H2 2014 124 Number of Products by Stage and Target, H2 2014 126 Number of Products by Stage and Mechanism of Action, H2 2014 130 Number of Products by Stage and Route of Administration, H2 2014 134 Number of Products by Stage and Molecule Type, H2 2014 136 Inflammatory Bowel Disease Therapeutics - Recent Pipeline Updates, H2 2014 304 Inflammatory Bowel Disease - Dormant Projects, H2 2014 332 Inflammatory Bowel Disease - Dormant Projects (Contd..1), H2 2014 333 Inflammatory Bowel Disease - Dormant Projects (Contd..2), H2 2014 334 Inflammatory Bowel Disease - Dormant Projects (Contd..3), H2 2014 335 Inflammatory Bowel Disease - Dormant Projects (Contd..4), H2 2014 336 Inflammatory Bowel Disease - Dormant Projects (Contd..5), H2 2014 337 Inflammatory Bowel Disease - Dormant Projects (Contd..6), H2 2014 338 Inflammatory Bowel Disease - Dormant Projects (Contd..7), H2 2014 339 Inflammatory Bowel Disease - Dormant Projects (Contd..8), H2 2014 340 Inflammatory Bowel Disease - Discontinued Products, H2 2014 341
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
